Clemens Unger

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

Andrea Kraft, Karin Weindel, Andreas Ochs et al. · Cancer · 1999 · 369 citations

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Clinical Cancer Research · 2012 · 329 citations

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Joachim Drevs, Ilse Hofmann, Harald Hugenschmidt et al. · PubMed · 2000 · 309 citations

Urology, Angiogenesis, Oncology +15

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger et al. · Journal of Clinical Oncology · 2007 · 302 citations

Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound

Felix Kratz, André Warnecke, Karin Scheuermann et al. · Journal of Medicinal Chemistry · 2002 · 271 citations